Revance Therapeutics (RVNC) to Offer Common Stock

Revance Therapeutics, Inc. (Nasdaq: RVNC) announced a proposed underwritten public offering of its common stock. The Company intends to use the net proceeds received from its offering of common stock to continue to fund the commercialization of DAXI, and the remainder for working capital, research and development and general corporate purposes. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Cowen, Piper Jaffray & Co. and Stifel are acting as book-running managers for the proposed offering.

You May Also Be Interested In

• Zentalis Pharmaceuticals prices $80.5M public stock offering
• Celcuity Inc (CELC) PT Lowered to $150 at Stifel as Gedatolisib Distribution Initiated
• Yeti Holdings Inc. (YETI) PT Raised to $45 at Stifel on Beat and Raise Q2 Results